Strang, BL
(2017)
RO0504985 is an inhibitor of CMGC kinase proteins and has anti-human cytomegalovirus activity.
Antiviral Res, 144.
pp. 21-26.
ISSN 1872-9096
https://doi.org/10.1016/j.antiviral.2017.05.004
SGUL Authors: Strang, Blair Lewis
Microsoft Word (.docx)
Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (162kB) |
||
|
Image (TIFF) (Figure 1)
Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (1MB) | Preview |
|
|
Image (TIFF) (Figure 2)
Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (1MB) | Preview |
|
|
Image (TIFF) (Figure 3)
Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (3MB) | Preview |
|
|
Image (TIFF) (Supplementary Figure 1)
Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (1MB) | Preview |
|
Microsoft Word (.docx) (Supplemntary material)
Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (110kB) |
||
Other (Supplementary table)
Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (78kB) |
Abstract
Public-private partnerships allow many previously unavailable compounds to be screened for antiviral activity. Here a screening method was used to identify an oxindole compound, RO0504985, from a Roche kinase inhibitor library that inhibited human cytomegalovirus (HCMV) protein production. RO0504985 was previously described as an inhibitor of cyclin-dependent kinase 2 (CDK2). However, using kinase selectivity assays it was found that RO0504985 was an inhibitor of several CMGC group kinase proteins, including CDK2. Using virus yield reduction assays it was observed that RO0504985 inhibited replication of different HCMV strains at low micromolar concentrations. Western blotting was used to investigate how RO0504985 inhibited HCMV replication. Treatment of HCMV infected cells with RO0504985 inhibited production of the immediate early viral IE2 proteins and the late viral protein pp28. Thus, RO0504985 inhibited HCMV replication by preventing production of specific HCMV proteins necessary for virus replication.
Item Type: | Article | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Additional Information: | © 2017. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ | |||||||||
Keywords: | CDK, CMGC, Cytomegalovirus, Human, Kinase, Screen, Virology, 1108 Medical Microbiology, 1115 Pharmacology And Pharmaceutical Sciences | |||||||||
SGUL Research Institute / Research Centre: | Academic Structure > Infection and Immunity Research Institute (INII) | |||||||||
Journal or Publication Title: | Antiviral Res | |||||||||
ISSN: | 1872-9096 | |||||||||
Language: | eng | |||||||||
Dates: |
|
|||||||||
Publisher License: | Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0 | |||||||||
Projects: |
|
|||||||||
PubMed ID: | 28501424 | |||||||||
Go to PubMed abstract | ||||||||||
URI: | https://openaccess.sgul.ac.uk/id/eprint/108889 | |||||||||
Publisher's version: | https://doi.org/10.1016/j.antiviral.2017.05.004 |
Statistics
Actions (login required)
Edit Item |